Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients
QaLM
1 other identifier
observational
173
1 country
7
Brief Summary
The purpose of this study is to determine which Health Related Quality of Life (HRQoL) tools patients with medullary thyroid cancer (MTC) find most helpful. The study will compare a generic cancer QoL tool with those developed for thyroid cancer patients and neuroendocrine tumour (NET) patients. The study will also evaluate clinicians' opinions on the clinical usefulness of the QoL tools.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2015
Typical duration for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2015
CompletedFirst Posted
Study publicly available on registry
June 8, 2015
CompletedStudy Start
First participant enrolled
December 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2017
CompletedMay 22, 2018
May 1, 2018
2.1 years
June 1, 2015
May 21, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ranking of quality of life assessment tool by patients
At recruitment
Study Arms (1)
questionnaire order
the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
Interventions
Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
Eligibility Criteria
Medullary thyroid cancer patients who are attending a thyroid cancer clinic in tertiary care setting in the NHS
You may qualify if:
- Patients 16 years old or over who have a diagnosis of medullary thyroid cancer (inherited or sporadic)
- Patients can be included at any time point after diagnosis
You may not qualify if:
- Patients who have differentiated (papillary or follicular) thyroid cancer or anaplastic thyroid cancer or lymphoma of the thyroid.
- Patients who do not sufficiently understand the English language or patients with learning disabilities, as these are standardised and validated questionnaires that are in English.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
Velindre Hospital
Cardiff, CF14 2TL, United Kingdom
University Hospitals of Coventry and Warwickshire
Coventry, United Kingdom
Western general Hospital
Edinburgh, United Kingdom
Imperial Hospital
London, United Kingdom
St. Bartholomew's Hospital
London, United Kingdom
Christie Hospital
Manchester, United Kingdom
Weston Park Hospital
Sheffield, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laura Moss, MB BCh
Velindre NHS Trust
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Consultant Clinical Oncologist
Study Record Dates
First Submitted
June 1, 2015
First Posted
June 8, 2015
Study Start
December 1, 2015
Primary Completion
December 31, 2017
Study Completion
December 31, 2017
Last Updated
May 22, 2018
Record last verified: 2018-05